Defining high, medium and low impact prognostic factors for developing multiple sclerosis

Brain

Volumn 138, Issue 7, 2015, Pages 1863-1874

  Tintore, Mar ^a   Rovira, Àlex ^b   Río, Jordi ^a   Otero Romero, Susana ^a   Arrambide, Georgina ^a   Tur, Carmen ^a   Comabella, Manuel ^a   Nos, Carlos ^a   Arévalo, María Jesús ^a   Negrotto, Laura ^a   Galán, Ingrid ^a   Vidal Jordana, Angela ^a   Castilló, Joaquin ^a   Palavra, Filipe ^a   Simon, Eva ^a   Mitjana, Raquel ^b   Auger, Cristina ^b   Sastre Garriga, Jaume ^a   Montalban, Xavier ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

clinically isolated syndromes; demyelination; epidemiology; imaging; multiple sclerosis

Indexed keywords

OLIGOCLONAL BAND;

ADULT; ARTICLE; DEMOGRAPHY; DISABILITY; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; SEX RATIO; BRAIN; CEREBROSPINAL FLUID; COHORT ANALYSIS; DEMYELINATING DISEASE; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

ADULT; BRAIN; COHORT STUDIES; DEMYELINATING DISEASES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OLIGOCLONAL BANDS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 84936805166     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv105     Document Type: Article

References (36)

1. Andersson M, Alvarez-Cermeno J, Bernardi G, Cogato I, Fredman P, Frederiksen J, et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry 1994; 57: 897-902.
2. Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997; 120 (Pt 11): 2059-69.
3. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-82.
4. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 1503-11. doi: 10.1016/S0140-6736(09)61259-9.
5. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain 2006a; 129 (Pt 3): 595-605. doi: 10.1093/brain/awh714.
6. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006b; 129 (Pt 3): 606-16. doi: 10.1093/brain/awl007.
7. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003; 126 (Pt 4): 770-82.
8. Di Filippo M, Anderson VM, Altmann DR, Swanton JK, Plant GT, Thompson AJ, et al. Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 2010; 81: 204-208. doi: 10.1136/jnnp.2009.171769.
9. Dobson R, Ramagopalan S, Davis A, Giovannoni G. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry 2013; 84: 909-14. doi: 10.1136/jnnp-2012-304695.
10. Dobson R, Ramagopalan S, Giovannoni G. The effect of gender in clinically isolated syndrome (CIS): a meta-analysis. Mult Scler 2012; 18: 600-4. doi: 10.1177/1352458511426740.
11. Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, et al. Disability and T2 MRI lesions: a 20-year followup of patients with relapse onset of multiple sclerosis. Brain 2008; 131 (Pt 3): 808-17. doi: 10.1093/brain/awm329.
12. Group ONS. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 2008; 65: 727-32. doi: 10.1001/archneur.65.6.727.
13. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343: 898-904. doi: 10.1056/NEJM200009283431301.
14. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242-49. doi: 10.1212/01.wnl.0000237641.33768.8d.
15. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401. doi: 10.1056/NEJMoa0909494.
16. Koch M, Kingwell E, Rieckmann P, Tremlett H. The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2010; 81: 1039-43. doi: 10.1136/jnnp.2010.208173.
17. Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010; 9: 520-32. doi: 10.1016/S1474-4422(10)70064-8.
18. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
19. Leray E, Yaouanq J, Le Page E, Coustans M, Laplaud D, Oger J, Edan G. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010; 133 (Pt 7): 1900-13. doi: 10.1093/brain/awq076.
20. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-7.
21. Mowry EM, Pesic M, Grimes B, Deen SR, Bacchetti P, Waubant E. Clinical predictors of early second event in patients with clinically isolated syndrome. J Neurol 2009; 256: 1061-6. doi: 10.1007/s00415-009-5063-0.
22. Polman C, Kappos L, Freedman MS, Edan G, Hartung HP, Miller DH, et al. Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. J Neurol 2008; 255: 480-7. doi: 10.1007/s00415-007-0733-2.
23. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302. doi: 10.1002/ana.22366.
24. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58: 840-6. doi: 10.1002/ana.20703.
25. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31. doi: 10.1002/ana.410130302.
26. Renoux C, Vukusic S, Mikaeloff Y, Edan G, Clanet M, Dubois B, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med 2007; 356: 2603-13. doi: 10.1056/NEJMoa067597.
27. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993; 116 (Pt 1): 117-34.
28. Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010; 133 (Pt 7): 1914-29. doi: 10.1093/brain/awq118.
29. Sellner J, Kraus J, Awad A, Milo R, Hemmer B. Stuve OThe increasing incidence and prevalence of female multiple sclerosis-A critical analysis of potential environmental factors. Autoimmun Rev 2011; 10: 495-502. doi: 10.1016/j.autrev.2011.02.006.
30. Tintore M, Rovira A, Martinez MJ, Rio J, Diaz-Villoslada P, Brieva L, et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol 2000; 21: 702-6.
31. Tintore M, Rovira A, Rio J, Nos C, Grive E, Tellez N, et al. Is optic neuritis more benign than other first attacks in multiple sclerosis? Ann Neurol 2005; 57: 210-15. doi: 10.1002/ana.20363.
32. Tintore M, Rovira A, Rio J, Nos C, Grive E, Tellez N, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006; 67: 968-72. doi: 10.1212/01.wnl.0000237354.10144.ec
33. Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 2006; 66: 172-7. doi: 10.1212/01.wnl.0000194259.90286.fe.
34. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989a; 112 (Pt 6): 1419-28.
35. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989b; 112 (Pt 1): 133-46.
36. Young J, Quinn S, Hurrell M, Taylor B. Clinically isolated acute transverse myelitis: prognostic features and incidence. Mult Scler 2009; 15: 1295-302. doi: 10.1177/1352458509345906.